Bruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.
Bruno Delagneau
Advertisement
Bruno Delagneau, M.D. is currently a consultant for pharmaceutical and biotech companies. He is the former CEO and founder of Idekos, a privately funded biotech company and a former Vice President at Gilead Sciences.
Articles by Bruno Delagneau
Advertisement
Latest Updated Articles
Is the Price Right Figure 2Published: October 1st 2018 | Updated:
Is the Price Right? An Overview of US Pricing StrategiesPublished: November 1st 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
2
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
3
FDA Announces New Biosimilar-Targeted Draft Guidance
4
AI Built for Pharma—Out-of-the-Box Wins on Time, Risk, and ROI
5
